IL27 and Sepsis: IL-27R knock-out in mice shows increased resistance against secondary bacterial pneumonia in sepsis and protection against sepsis-induced lethality, whereas treatment with recombinant IL-27 confers susceptibility to Pseudomonas aeruginosa infection and enhanced lipopolysaccharide (LPS)-induced pro-inflammatory cytokine production [14–16].